SC
EW icon

Savant Capital’s Edwards Lifesciences EW Stock Holding History

Savant Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Buy
16,100
+475
+3% +$39.8K ﹤0.01% 716
2026
Q1 		$1.25M Sell
15,625
-92
-0.6% -$7.58K 0.01% 546
2025
Q4 		$1.34M Sell
15,717
-2,274
-13% -$187K 0.01% 494
2025
Q3 		$1.4M Buy
17,991
+6,284
+54% +$491K 0.01% 464
2025
Q2 		$916K Buy
11,707
+624
+6% +$46.5K 0.01% 547
2025
Q1 		$803K Buy
11,083
+88
+0.8% +$6.3K 0.01% 543
2024
Q4 		$814K Sell
10,995
-4,542
-29% -$318K 0.01% 724
2024
Q3 		$1.03M Sell
15,537
-11,728
-43% -$852K 0.01% 637
2024
Q2 		$2.52M Sell
27,265
-361
-1% -$32K 0.03% 319
2024
Q1 		$2.64M Buy
27,626
+17,903
+184% +$1.5M 0.03% 284
2023
Q4 		$741K Sell
9,723
-472
-5% -$32.8K 0.01% 478
2023
Q3 		$706K Sell
10,195
-151
-1% -$12.1K 0.01% 463
2023
Q2 		$976K Buy
10,346
+160
+2% +$13.9K 0.02% 385
2023
Q1 		$843K Sell
10,186
-175
-2% -$13.8K 0.02% 362
2022
Q4 		$773K Sell
10,361
-26
-0.3% -$2K 0.02% 301
2022
Q3 		$858K Sell
10,387
-606
-6% -$58.3K 0.03% 251
2022
Q2 		$1.04M Buy
10,993
+127
+1% +$13.1K 0.03% 225
2022
Q1 		$1.28M Buy
10,866
+123
+1% +$13.8K 0.04% 210
2021
Q4 		$1.39M Buy
10,743
+3,303
+44% +$385K 0.05% 207
2021
Q3 		$842K Buy
7,440
+365
+5% +$41.7K 0.03% 236
2021
Q2 		$733K Buy
7,075
+76
+1% +$7.16K 0.03% 242
2021
Q1 		$585K Sell
6,999
-79
-1% -$6.68K 0.03% 259
2020
Q4 		$646K Sell
7,078
-615
-8% -$51K 0.04% 234
2020
Q3 		$614K Buy
7,693
+75
+1% +$5.85K 0.04% 226
2020
Q2 		$526K Buy
7,618
+742
+11% +$52.7K 0.04% 236
2020
Q1 		$432K Buy
6,876
+4,143
+152% +$299K 0.04% 244
2019
Q4 		$213K Buy
+2,733
New +$213K 0.03% 333

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Savant Capital's EW Position: Q2 2026 in Review

Savant Capital increased its Edwards Lifesciences (EW) stake by 3% in Q2 2026, buying an estimated $39.8K and bringing the position to 16,100 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #716.

Savant Capital first reported a position in EW in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.64M in Q1 2024. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Savant Capital held 16,100 shares of Edwards Lifesciences worth $1.46M as of Q2 2026.
  • Savant Capital bought 475 Edwards Lifesciences shares in Q2 2026, an estimated $39.8K.
  • Edwards Lifesciences made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #716 holding.
  • Savant Capital first reported a position in Edwards Lifesciences in Q4 2019 and has held it in 27 quarters since.
  • Savant Capital's Edwards Lifesciences position peaked at $2.64M in Q1 2024.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.